The DEBRA study is a Phase III trial that checks if two treatments for certain breast cancers work equally well. These breast cancers are sensitive to hormones and HER2-negative. Normally, after breast-conserving surgery, women need radiation therapy and hormone therapy to lower the chance of cancer coming back. This study checks if skipping radiation therapy is just as effective when combined with hormone therapy.

Key Points:

• The study involves comparing breast conservation surgery with or without radiation therapy but with hormone therapy.
• Participants must have had surgery to remove the cancer and plan to take hormone therapy for at least 5 years.
• Women who join should ensure they don’t have metastatic disease and haven't had any prior radiation or chemotherapy for this cancer.

**Hormone Sensitivity**: This means the cancer grows in response to hormones like estrogen. **HER2-Negative** means the cancer doesn’t have excess HER2 protein, which affects growth. **Ipsilateral** refers to the same side of the body. The trial helps understand if some patients can safely skip radiation and still prevent cancer from returning. Before joining, patients must have a recent mammogram or MRI and be in good health after surgery.